Screener
IBB vs XBI
iShares Biotechnology ETF vs State Street SPDR S&P Biotech ETF
Key differences
- XBI costs 0.09% less per year.
- Over the last 3 years, XBI has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IBB | XBI | |
|---|---|---|
| Annual cost (TER) | 0.44% | 0.35% |
| Fund size (AUM) | $7.9B | $8.3B |
| Since | 2001 | 2006 |
| Dividend yield | 0.23% | 0.34% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +39.0% | +66.6% |
| CAGR 3Y | +9.6% | +15.6% |
| CAGR 5Y | +2.7% | +0.9% |
| Sharpe 3Y | 0.38 | 0.54 |
| Volatility 1Y | 19.75% | 25.14% |
| Max drawdown | -39.82% | -63.89% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IBB and XBI
Explore further